View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 19, 2017

Abide doses first patient in Phase Ib trial of ABX-1431 to treat tourette syndrome

US-based Abide Therapeutics has started dosing patients in a Phase Ib clinical trial of ABX-1431 for the treatment of tourette syndrome (TS).

US-based Abide Therapeutics has started dosing patients in a Phase Ib clinical trial of ABX-1431 for the treatment of tourette syndrome (TS).

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Abide has also partnered with the Tourette Association of America (TAA) to understand the unmet needs in the Tourette community.

ABX-1431 is an investigational, orally available, small-molecule monoacylglycerol lipase (MGLL) inhibitor.

The cross-over Phase 1b trial will evaluate the ability of ABX-1431 to modulate the endocannabinoid neurotransmitter system activity.

The trial aims to determine the effect of a highly specific endocannabinoid modulator when assessed under controlled conditions compared to established benefits of exocannabinoids.

"Following the completion of dosing in the Phase Ia trial, ABX-1431 was found to be well tolerated without any serious adverse events."

Abide Therapeutics president and chief executive officer Alan Ezekowitz said: "We are excited to begin this trial in adults with Tourette Syndrome, and we hope to subsequently extend our studies to children, since Tourette Syndrome is largely considered to be a disease of childhood.

"As we continue to explore the potential utility of ABX-1431 in Tourette Syndrome, we are grateful for the opportunity to partner with the TAA to further understand the challenges faced by those affected by the condition."

Following the completion of dosing in the Phase Ia trial, ABX-1431 was found to be well tolerated without any serious adverse events.

According to the preliminary data from a PET occupancy study, ABX-1431 showed dose-dependent brain penetrance via Abide's MGLL-specific PET ligand known as [18F]ABX-1488.

Additionally, the firm is planning to begin dosing patients in a fMRI trial investigating ABX-1431-related neural activity patterns in the brain.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena